Frontiers in Cell and Developmental Biology (Jun 2021)
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity
- Xinyue Song,
- Xinyue Song,
- Xinyue Song,
- Xinyue Song,
- Xue Jiao,
- Xue Jiao,
- Xue Jiao,
- Xue Jiao,
- Han Yan,
- Han Yan,
- Han Yan,
- Han Yan,
- Lifeng Yu,
- Lifeng Yu,
- Lifeng Yu,
- Lifeng Yu,
- Longyang Jiang,
- Longyang Jiang,
- Longyang Jiang,
- Longyang Jiang,
- Ming Zhang,
- Ming Zhang,
- Ming Zhang,
- Ming Zhang,
- Lianze Chen,
- Lianze Chen,
- Lianze Chen,
- Lianze Chen,
- Mingyi Ju,
- Mingyi Ju,
- Mingyi Ju,
- Mingyi Ju,
- Lin Wang,
- Lin Wang,
- Lin Wang,
- Lin Wang,
- Qian Wei,
- Qian Wei,
- Qian Wei,
- Qian Wei,
- Lin Zhao,
- Lin Zhao,
- Lin Zhao,
- Lin Zhao,
- Minjie Wei,
- Minjie Wei
Affiliations
- Xinyue Song
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Xinyue Song
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Xinyue Song
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Xinyue Song
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Xue Jiao
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Xue Jiao
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Xue Jiao
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Xue Jiao
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Han Yan
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Han Yan
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Han Yan
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Han Yan
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Lifeng Yu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Lifeng Yu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Lifeng Yu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Lifeng Yu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Longyang Jiang
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Longyang Jiang
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Longyang Jiang
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Longyang Jiang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Ming Zhang
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Ming Zhang
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Ming Zhang
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Ming Zhang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Lianze Chen
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Lianze Chen
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Lianze Chen
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Lianze Chen
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Mingyi Ju
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Mingyi Ju
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Mingyi Ju
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Mingyi Ju
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Lin Wang
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Lin Wang
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Lin Wang
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Lin Wang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Qian Wei
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Qian Wei
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Qian Wei
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Qian Wei
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Lin Zhao
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Lin Zhao
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Lin Zhao
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Lin Zhao
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Minjie Wei
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Minjie Wei
- Shenyang Kangwei Medical Laboratory Analysis Co. LTD., Shenyang, China
- DOI
- https://doi.org/10.3389/fcell.2021.622018
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundLung adenocarcinoma (LUAD) is the most common diagnostic histologic subtype of non-small cell lung cancer, but the role of receptor-type tyrosine-protein phosphatase-like N (PTPRN) in LUAD has not been studied.MethodsWe conducted a bioinformatic analysis to identify the expression of PTPRN on LUAD data from the Cancer Genome Atlas (TCGA) and the relationship between PTPRN and overall survival of LUAD patients. The effects of PTPRN on the migration ability of LUAD cells and the underlying mechanisms were investigated by in vitro and in vivo assays (i.e., wound healing assay, transwell assay, western blotting, xenograft model, and immunohistochemistry). Gene-set enrichment analysis and computational resource were used to analyze the correlation between PTPRN and different tumor-infiltrating immune cells (TIICs). Lactate dehydrogenase assay and Enzyme-linked immunosorbent assay were conducted to examine natural killer (NK) cell cytotoxicity.ResultsIn our study, we found that PTPRN was up-regulated in LUAD and related to metastasis of LUAD patients. Besides, PTPRN was correlated with poor prognosis in the TCGA-LUAD dataset. PTPRN overexpression promoted LUAD cell migration and the expression of EMT markers by influencing MEK/ERK and PI3K/AKT signaling. Moreover, PTPRN expression was significantly associated with TIICs, especially NK cells. A549 and H1299 cells overexpressed PTPRN inhibited NK cell cytotoxicity.ConclusionTaken together, these findings demonstrated that PTPRN might be a potential and novel therapeutic target modulating antitumor immune response in treatment of LUAD.
Keywords
